ClinicalTrials.gg
CompletedNCT05216809ARBTUpdated Nov 19, 2026

Oral 'Breath Test' to Measure Anabolic Sensitivity in Young and Older Adults at Different Activity Levels

An interventional study of Habitual Physical Activity and Step-Reduction in Sedentary Behavior, Aging and Sarcopenia, sponsored by University of Toronto. Completed at 1 site in Canada. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Toronto · Not applicable, Interventional, and Other

How we know

Updated Nov 19, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 73 studies in Sedentary Behavior with a site in Canada — 18 open to participants now, 19 under way, none of them phase 3. Sedentary Behavior · Canada.

Enrollment
45th of 69
32 · median 50
Started
2022
with 10 others
No phase
67 of 73
18 open now
Registered
37th of 73
by date
Lead sponsor
9 of 73
University of Toronto

Among the 73 studies in Sedentary Behavior with a site in Canada, this one is the 45th largest by enrollment of the 69 interventional ones that give a count, is one of 11 that started in 2022, is one of 67 with no phase, and was the 37th registered.

Sedentary Behavior

1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.

Browse Sedentary Behavior studies →

Open to participants now

18 of the 73 studies in Sedentary Behavior with a site in Canada are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Sedentary Behavior with a site in Canada, or all of them as a file.
02

Study summary

Recent work in the investigators laboratory has examined the ability of a non-invasive 13CO2 breath-test to assess differences in amino acid oxidation rates and net balance in young healthy males following protein feeding and resistance exercise. The investigators aim to test the efficacy of this non-invasive 13CO2 breath-test to assess for differences in anabolic sensitivity between young and older adults following an acute period of habitual and reduced physical activity.

Read the detailed description

Aging is associated with a phenomenon known as anabolic resistance, whereby individuals are less responsive to anabolic stimuli (i.e., resistance exercise, dietary protein ingestion). Mild and severe reductions in physical activity are also known to play a key role in the emergence of anabolic resistance. Therefore, the purpose of this study is to investigate the ability of a non-invasive 13CO2 breath-test to assess differences in whole-body leucine oxidation and leucine net balance between younger and older individuals under conditions of habitual activity and following a period of reduced activity/step-reduction. In this manner, the ability of the methodology to distinguish anabolic sensitivity between young and older adult populations will be assessed.

Methods:

Total participant time commitment will span over 4 sessional dates:

Session 1 - Introduction Interested participants will be recruited to engage in a video conference call to undergo an introductory session. Participants will be provided with a comprehensive introduction to the study which will explain the research objectives, conduct, and associated risks. Participants will provide informed consent prior to the collection of any study information (i.e., anthropometrics and habitual activity levels). Eligibility will also be screened for at this time.

Session 2 - Body Composition Assessment Participants will consume a bolus of deuterium oxide (D2O) and provide saliva samples in order to estimate fat-free mass.

The remainder of the study will consist of seven consecutive days, wherein Phase 1 (Habitual Activity) will be subsequently followed by Phase 2 (Step-Reduction).

Phase 1 - Habitual Activity (Days 1-3) Participants will be asked to engage in their habitual activity pattern (> 7000 steps/day) while wearing an accelerometer and pedometer. Participants will be further instructed to maintain their normal dietary patterns and to track their diets over the course of these three days using diet logs.

Session 3 - Habitual Activity Metabolic Trial (Day 4) On the morning of the fourth day, following three days of habitual activity, participants will be subjected to the non-invasive 13CO2 breath-test to assess for whole-body leucine oxidation and net balance. This date will also serve as a lead-in to the subsequent Phase 2.

Phase 2 - Step-Reduction (Days 4-6) Participants will be asked to maintain their normal dietary patterns and track their dietary intake, but will need to adhere to a reduced daily step count (\<2000 steps/day). Accelerometers and pedometers will be worn again during this period.

Session 4 - Step-Reduction Metabolic Trial (Day 7) On the morning of the 7th day, following three days of reduced daily step-count, participants will be subjected again to the non-invasive 13CO2 breath-test to assess for whole-body leucine oxidation and net balance. Ultimately, this will allow us to determine whether 3-days of reduced step-count will impart any changes on anabolic sensitivity.

For each metabolic trial, two urine samples (baseline and pooled enriched) will be collected, in addition to breath samples collected over a 6-hour post-prandial period at 20-30 minute intervals. These biological samples will be used to measure tracer excretion and oxidation, allowing us to determine rates of protein metabolism.

03

Conditions studied

  • Sedentary Behavior
  • Aging
  • Sarcopenia
  • Amino Acids
  • Dietary Protein

Keywords

  • Skeletal Muscle
  • Step-Reduction
  • Aging
  • Anabolic Resistance
  • Physical Activity
  • Stable Isotopes
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy young (age: 18-35 years) or older (age: 60-80 years) adults
  • Average daily step-count >7,000/day
  • between normal to overweight (18.5-29.9 kg/m2)

Exclusion criteria

Exclusion Criteria:

  • Regular use of nonsteroidal anti-inflammatory drugs (with the exception of daily low-dose aspirin)
  • Use of anticoagulants
  • Use of a walker, cane, or assistive walking device
  • Current or recently remised cancer
  • Infectious or gastrointestinal disease
  • Inability to comply with study protocol (e.g., >2,000 steps/day during Step-Reduction Phase)
  • Regular tobacco use
  • Self-reported illicit drug use (e.g. growth hormone, testosterone, etc.)
  • Diagnosed chronic illness (e.g. type 2 diabetes, heart disease, thyroid disease)
  • Pregnant
  • Hormonal Replacement Therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Young Adults

    Equal sex distribution (10M/10F); ages 18-35 years old.

    Behavioral: Habitual Physical Activity · Behavioral: Step-Reduction

  • Active comparator
    Older Adults

    Equal sex distribution (6M/6F); ages 60-80 years old.

    Behavioral: Habitual Physical Activity · Behavioral: Step-Reduction

Interventions

  • BehavioralHabitual Physical Activity

    Participants will maintain habitual levels of physical activity (inclusive of structured physical activity). Participants will be required to maintain \>7,000 steps/day.

    Also known as: Free-Living Activity

  • BehavioralStep-Reduction

    Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.

    Also known as: Reduced Physical Activity

06

What researchers measure

Primary outcomes

  1. Exogenous Leucine Oxidation (umol/kg)

    Exogenous Leucine Oxidation determined from breath 13CCO2 enrichment. Breath samples will be collected every 20-30min after test drink ingestion to determine breath 13CO2 enrichment. Total leucine oxidation will be determined from the area under the 13CO2 enrichment by time curve.

    Time frame: 6 hours

  2. Net Leucine Retention (umol/kg)

    Whole-Body Net Leucine Retention determined from the difference between exogenous leucine oxidation and leucine ingestion the 6 hour measurement period.

    Time frame: 6 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Mar 2024, 25 months.

Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's 25 months is above that.

Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2024 → Mar 2024, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2021
First posted
Feb 1, 2022
StartActual
Feb 1, 2022
Primary completionActual
Mar 31, 2024was Jan 2024
CompletionActual
Mar 31, 2024
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 19, 2026
Primary completion
Jan 1, 2024→Mar 31, 2024 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Completed
    Primary completion Jan 1, 2024→Mar 31, 2024 (now actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05216809
Responsible party
Daniel Moore (Principal Investigator, University of Toronto) — Principal investigator
First posted
Feb 1, 2022
Start date
Feb 1, 2022
Primary completion
Mar 31, 2024
Completion
Mar 31, 2024
Last update
Nov 19, 2026

Study contacts

Daniel Moore, PhD
principal investigator · University of Toronto
Hugo JW Fung, PhD (c)
study director · University of Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion